Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR138 T-Cells in Relapsed or Refractory Multiple Myeloma
NCT03672318Phase 1Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2019
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD138-specific CAR T cells in multiple myeloma (MM), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Proportion of participants with dose limiting toxicities at 4 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
CD138-specific CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03672318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672318.